Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 17 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is Uniquely Positioned to Fill a Major Processing Gap in Quebec’s Abitibi Gold Belt with Its Beacon Mill
LaFleur Minerals acquired the fully permitted and refurbished Beacon Gold Mill at a steep discount…
-
Vivakor Inc. (NASDAQ: VIVK): A Modern Answer to Oil’s Dirty Problem
Vivakor’s Q1 2025 revenue soared 133% year-over-year to $37.3 million The company announced a special…
-
BluSky AI Inc. (BSAI) Is ‘One to Watch’
BluSky AI delivers mission-critical infrastructure supporting AI, ML, and HPC applications. SkyMod modules are prefabricated,…